# Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting

> **NCT05048589** · PHASE2 · COMPLETED · sponsor: **Tor Biering-Sørensen** · enrollment: 12551 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Standard-Dose Quadrivalent Influenza Vaccine
- **DRUG:** High-Dose Quadrivalent Influenza Vaccine

## Key facts

- **NCT ID:** NCT05048589
- **Lead sponsor:** Tor Biering-Sørensen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-01
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 12551 (ACTUAL)
- **Last updated:** 2022-08-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05048589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05048589, "Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05048589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*